Journal of Applied Physiology, Vol 57, Issue 4 1173-1181, Copyright © 1984 by American Physiological Society

ARTICLES

Kinetics of pulmonary angiotensin-converting enzyme and 5'-nucleotidase in vivo

J. D. Catravas and R. E. White

Angiotensin-converting enzyme and 5'-nucleotidase line the luminal surface of pulmonary microvascular endothelium and participate in the synthesis and/or degradation of potent vasoactive substances. We applied Michaelis-Menten kinetics in simultaneous estimations of apparent constants Km and Amax (product of Vmax and microvascular plasma volume) of these two enzymes for the substrates 3H-labeled benzoyl-Phe-Ala-Pro and 14C-labeled 5'-AMP, respectively, in vivo. Values of angiotensin-converting enzyme for benzoyl-Phe-Ala-Pro (Km = 10-11 microM; Amax = 12-13 mumol X min-1) were somewhat higher than published estimates in vitro and changed predictably in response to the known enzyme inhibitor captopril. Kinetic values of 5'-nucleotidase for 5'-AMP (Km = 3-4 microM; Amax = 3-4 mumol/min) were substantially lower than those reported in vitro but also responded predictably to the competitive inhibitor of 5'-nucleotidase, adenosine 5'-[alpha, beta-methylene]diphosphate. These data offer in vivo estimates of enzyme kinetics that are useful in revealing enzyme behavior in their normal physiological environment and provide means of evaluating the action of pharmacological, physiological, and pathological modulators of enzyme activity, in vivo.

This article has been cited by other articles:

				K. Jules-Elysee, T. J. J. Blanck, J. D. Catravas, G. Chimento, A. Miric, R. Kahn, L. Paroli, and T. Sculco Angiotensin-Converting Enzyme Activity: A Novel Way of Assessing Pulmonary Changes During Total Knee Arthroplasty Anesth. Analg., October 1, 2004; 99(4): 1018 - 1023. [Abstract] [Full Text] [PDF]

				S. E. Orfanos, A. Armaganidis, C. Glynos, E. Psevdi, P. Kaltsas, P. Sarafidou, J. D. Catravas, U. G. Dafni, D. Langleben, and C. Roussos Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Acute Lung Injury Circulation, October 17, 2000; 102(16): 2011 - 2018. [Abstract] [Full Text] [PDF]

				S. E. Orfanos, J. B. Parkerson, X. Chen, E. L. Fisher, C. Glynos, A. Papapetropoulos, R. G. Gerrity, and J. D. Catravas Reduced lung endothelial angiotensin-converting enzyme activity in Watanabe hyperlipidemic rabbits in vivo Am J Physiol Lung Cell Mol Physiol, June 1, 2000; 278(6): L1280 - L1288. [Abstract] [Full Text] [PDF]

				S. E. Orfanos, D. Langleben, J. Khoury, R. D. Schlesinger, L. Dragatakis, C. Roussos, J. W. Ryan, and J. D. Catravas Pulmonary Capillary Endothelium-Bound Angiotensin-Converting Enzyme Activity in Humans Circulation, March 30, 1999; 99(12): 1593 - 1599. [Abstract] [Full Text] [PDF]

				X. Chen and J. D. Catravas Release of a leukocyte activation inhibitor by staurosporine-treated pulmonary artery endothelial cells Am J Physiol Lung Cell Mol Physiol, July 1, 1998; 275(1): L184 - L192. [Abstract] [Full Text] [PDF]

				L. E. Fisher Jr., A. Cziraki, C. M. Steinhart, and J. D. Catravas Unaltered pulmonary capillary surface area in the presence of changing arterial resistance Am J Physiol Lung Cell Mol Physiol, February 1, 1998; 274(2): L264 - L269. [Abstract] [Full Text] [PDF]

				S. Prié, T. K. Leung, P. Cernacek, J. W. Ryan, and J. Dupuis The Orally Active ETA Receptor Antagonist (+)-(S)-2-(4,6-dimethoxy-pyrimidin-2-yloxy)-3-methoxy-3,3-diphenyl-propionic acid (LU 135252) Prevents the Development of Pulmonary Hypertension and Endothelial Metabolic Dysfunction in Monocrotaline-Treated Rats J. Pharmacol. Exp. Ther., September 1, 1997; 282(3): 1312 - 1318. [Abstract] [Full Text]